Sun Pharma Q1FY27 profit rises 27% as India formulations grow 16%
Sun Pharma reported Q1FY27 net profit of Rs 2,894.79 crore, up 27% year on year, while revenue rose 10.46% to Rs 15,299.88 crore. India formulations sales grew 16% to Rs 5,475 crore, lifting domestic market share to 8.5%.
What happened
Sun Pharma reported 27% YoY Q1FY27 profit growth as India formulations rose 16% to Rs 5,475 crore. Its domestic market share reached 8.5%, supported by five
Key facts
- Q1FY27 net profit: Rs 2,894.79 crore, up 27% YoY
- Q1FY27 revenue: Rs 15,299.88 crore, up 10.46% YoY
- India formulations sales: Rs 5,475 crore, up 16% YoY
- India formulations share of consolidated sales: 36.1%
- India market share: 8.5%, versus 8.2% a year earlier
- Five new domestic products launched
- EBITDA: Rs 4,418 crore, up 2.7% YoY
- EBITDA margin: 28.9%
- Exceptional acquisition-related charge: about Rs 204 crore
Why this matters
Sun Pharma’s faster-growing domestic formulations business and rising 8.5% market share strengthen its position for India-focused brand, distribution, and portfolio partnerships.
What to watch
- Whether India formulations growth stays above 12-15% over the next two quarters.
- Further movement in domestic market share above 8.5%, especially in chronic and specialty segments.
- Gross-margin and EBITDA-margin trends indicating whether growth is mix-led or being bought through higher selling expenses.
- US formulation sales, specialty portfolio performance and new product approvals.
- Any USFDA inspection observations, warning letters or manufacturing remediation disclosures.
- Competitor actions on pricing, doctor engagement and trade incentives in key Indian therapy areas.
- Increase promotion and field-force coverage in high-growth chronic therapy categories where domestic scale can be converted into prescription share.
- Use improved domestic profitability to accelerate branded launches, specialty products and selective bolt-on acquisitions.
- Defend distributor and pharmacy availability to prevent stock-outs as India formulations volumes rise.
- Emphasize India-market momentum in guidance while managing expectations for US generics, specialty sales and regulatory expenses.